Background: Dupilumab is a monoclonal antibody against the IL-4/IL-13 receptor-subunit approved for the treatment of moderate-severe atopic dermatitis (AD). Some attempts to increase dose interval have been described in both trial and real-world settings. Objective: This study aimed to identify predictive clinical and demographic factors affecting patient selection for dose spacing or treatment withdrawal due to satisfactory response. Materials and methods: This retrospective study included adult patients with moderate-to-severe AD treated with dupilumab for at least 16 weeks. Descriptive statistics were performed to analyze demographic and clinical variables. Logistic regression models were used to identify predictor variables. Results: A total of 818 adult patients with moderate-to-severe AD was included in the study and 12% (97/818) of them performed dose spacing to 3–4 weeks or treatment withdrawal (8%, 67/818). The presence of non-cutaneous atopic manifestations (OR = 1.59, 95%CI = 1.06–2.38, p = 0.024), prurigo nodularis phenotype (OR = 4.5, 95%CI = 1.87–10.9, p = 0.001) and the age at treatment initiation (OR = 1.82, 95%CI = 1.12–2.94, p = 0.015) were confirmed as the strongest predictors of dose spacing or treatment withdrawal while maintaining dupilumab effectiveness. Conclusion: Our findings contribute to define the patient profile that could maintain the therapeutic response after dose spacing or treatment withdrawal.

Chiricozzi, A., Dal Bello, G., Gori, N., Di Nardo, L., Schena, D., Caldarola, G., Maurelli, M., De Simone, C., Girolomoni, G., Peris, K., Identification of clinical predictors for dupilumab dose spacing in adults with atopic dermatitis: a real-world study, <<THE JOURNAL OF DERMATOLOGICAL TREATMENT>>, 2023; 34 (1): 2235041-N/A. [doi:10.1080/09546634.2023.2235041] [https://hdl.handle.net/10807/249076]

Identification of clinical predictors for dupilumab dose spacing in adults with atopic dermatitis: a real-world study

Chiricozzi, Andrea;Gori, Niccolo';Di Nardo, Lucia;Caldarola, Giacomo;De Simone, Clara;Peris, Ketty
2023

Abstract

Background: Dupilumab is a monoclonal antibody against the IL-4/IL-13 receptor-subunit approved for the treatment of moderate-severe atopic dermatitis (AD). Some attempts to increase dose interval have been described in both trial and real-world settings. Objective: This study aimed to identify predictive clinical and demographic factors affecting patient selection for dose spacing or treatment withdrawal due to satisfactory response. Materials and methods: This retrospective study included adult patients with moderate-to-severe AD treated with dupilumab for at least 16 weeks. Descriptive statistics were performed to analyze demographic and clinical variables. Logistic regression models were used to identify predictor variables. Results: A total of 818 adult patients with moderate-to-severe AD was included in the study and 12% (97/818) of them performed dose spacing to 3–4 weeks or treatment withdrawal (8%, 67/818). The presence of non-cutaneous atopic manifestations (OR = 1.59, 95%CI = 1.06–2.38, p = 0.024), prurigo nodularis phenotype (OR = 4.5, 95%CI = 1.87–10.9, p = 0.001) and the age at treatment initiation (OR = 1.82, 95%CI = 1.12–2.94, p = 0.015) were confirmed as the strongest predictors of dose spacing or treatment withdrawal while maintaining dupilumab effectiveness. Conclusion: Our findings contribute to define the patient profile that could maintain the therapeutic response after dose spacing or treatment withdrawal.
2023
Inglese
Chiricozzi, A., Dal Bello, G., Gori, N., Di Nardo, L., Schena, D., Caldarola, G., Maurelli, M., De Simone, C., Girolomoni, G., Peris, K., Identification of clinical predictors for dupilumab dose spacing in adults with atopic dermatitis: a real-world study, <<THE JOURNAL OF DERMATOLOGICAL TREATMENT>>, 2023; 34 (1): 2235041-N/A. [doi:10.1080/09546634.2023.2235041] [https://hdl.handle.net/10807/249076]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10807/249076
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 2
  • ???jsp.display-item.citation.isi??? ND
social impact